The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.
Jessica Russo, PharmD, MBA
Advertisement
Articles by Jessica Russo, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
2
From Stigma to Breakthrough: Psychedelic Medicine
3
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
4
CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution
5
